• Cellectis SA, of Paris, presented data at the European Society of Gene & Cell Therapy meeting in Versailles, France, showing that it can program cells from the immune system (T cells) to kill cancer cells. Cellectis' approach involves isolating cells from the immune systems of healthy patients and genetically programming them to attack cancer cells in sick patients.